Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Stupp protocol is a standard-of-care treatment regimen for newly diagnosed glioblastoma (GBM). Developed in 2005 by Roger Stupp and colleagues in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group, the protocol consists of maximal safe surgical resection of the tumor, followed by concurrent radiotherapy (60 Gy delivered in 30 daily fractions over 6 weeks) combined with daily oral chemotherapy using temozolomide (TMZ), and then adjuvant temozolomide chemotherapy for six 28-day cycles. Temozolomide is an alkylating agent that works by methylating DNA, targeting rapidly dividing tumor cells. The Stupp protocol is widely used as the standard comparator arm in clinical trials evaluating novel glioblastoma therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Stupp protocol.